Thyroid Eye Disease and Eyelid Surgery: Why Bulging Eyes, a Startled Stare, and Puffy Lids From Graves Disease Are Not a Routine Blepharoplasty Problem, How to Tell Active Disease From Stable Disease, Where Steroids, Teprotumumab, and Orbital Decompression Fit, and Why the Order of Operations Decides the Result

The patient is 41, works in sales, and books a blepharoplasty consultation because colleagues have started asking if everything is all right. The upper lids look heavy and full, the lower lids have bags, and in photographs the eyes look wide and slightly startled, which the patient reads as fatigue. The eyes also feel gritty by evening, and the patient has started wearing sunglasses indoors on bright days. A thyroid problem was treated with radioactive iodine two years ago and the blood tests have been normal since. The patient does not mention it, because it does not seem relevant to a cosmetic eyelid appointment.

It is the most relevant fact in the room. The fullness, the stare, and the grittiness together are a classic picture of thyroid eye disease, also called Graves orbitopathy or thyroid-associated orbitopathy. The condition changes the tissues behind and around the eye, and it changes what eyelid surgery can safely do. A routine upper and lower blepharoplasty on this patient, done without recognizing the disease, risks lids that no longer close, a lower lid that pulls further down, and a stare that looks worse rather than better.

This piece covers what thyroid eye disease is, the signs that separate it from ordinary aging, why the distinction between active and inactive disease drives every decision, where medical treatment now fits, and the order in which surgery should be done when it is needed. It builds on the earlier pieces on eyelid ptosis versus blepharoplasty, blepharoplasty for sagging skin and under-eye bags, and dry eye after eyelid surgery.

What thyroid eye disease is, and why it gets mistaken for aging

The short answer: thyroid eye disease is an autoimmune condition in which antibodies, most associated with Graves disease, activate cells in the orbit so the fat and eye muscles swell, pushing the eye forward and pulling the eyelids open; because the early look is puffy lids, bags, and a tired or staring expression, it is routinely mistaken for cosmetic aging.

The eye sits in a bony cone with one open end. In thyroid eye disease, antibodies that target the thyroid stimulating hormone receptor, along with signaling through the insulin-like growth factor 1 receptor, activate the connective tissue cells (fibroblasts) in the orbit. Those cells produce water-binding molecules and new fat, and the eye muscles enlarge, most often the inferior and medial rectus muscles. With nowhere else to go, the contents push the eye forward, a change called proptosis or exophthalmos.

Several facts make the condition easy to miss in a cosmetic setting:

• It is common in Graves disease. Estimates vary with how closely patients are examined, but roughly a quarter to a half of people with Graves disease show some eye involvement, and a much smaller share develop moderate to severe disease, according to the American Thyroid Association and European Group on Graves Orbitopathy (EUGOGO) guidance.
• Thyroid tests can be normal. A small share of patients have eye disease with normal thyroid function, sometimes before a thyroid diagnosis and sometimes with Hashimoto thyroiditis rather than Graves disease. Thyroid treatment does not switch the eye disease off; the eye runs on its own timeline.
• It can follow thyroid treatment. Radioactive iodine can trigger or worsen eye disease, particularly in smokers, which is why endocrinologists often give a short steroid course alongside it in at-risk patients.
• The early look is cosmetic. Fuller upper lids, a heavy brow fat pad, lower lid bags, and swelling over the cheekbone resemble the changes discussed in the piece on malar mounds and festoons. The stare is often read as alertness or anxiety.

Women are affected several times more often than men, but men and older patients tend to have more severe disease. Smoking is the strongest modifiable risk factor: smokers are more likely to develop the condition, more likely to have severe disease, and less likely to respond to treatment. The case for stopping before any operation, covered in the piece on pre-op smoking cessation timelines, is even stronger here, because quitting changes the course of the eye disease itself.

"

Thyroid eye disease does not read as a disease in the mirror. It reads as tired eyes, heavy lids, and bags, which is exactly why it ends up in a cosmetic consultation instead of an orbit clinic.

"

The practical consequence is that any eyelid consultation should include a direct question about thyroid history, and any patient with a thyroid history should volunteer it, even years after treatment and even with normal blood tests.

How to tell whether puffy or bulging eyes are thyroid-related

The short answer: the features that point toward thyroid eye disease rather than aging are upper lid retraction with visible white above the iris, a lid that lags behind the eye when looking down, a temporal flare to the upper lid, asymmetric forward position of the eyes, redness over the muscle insertions, double vision, and grittiness or light sensitivity; a measurement of eye prominence and, when needed, orbital imaging confirm it.

Aging lids droop. Thyroid lids retract. That single distinction is the most useful one a patient or surgeon can make. In ordinary aging, the upper lid margin sits at or slightly below the top of the iris, and the problem is excess skin hanging over it, the hooding described in the piece on hooded eyes versus brow ptosis. In thyroid eye disease, the upper lid is pulled up, often exposing a band of white above the iris, because the Müller muscle that holds the lid open is overactive and the levator muscle becomes inflamed and later scarred.

The signs worth looking for:

• Upper lid retraction. White sclera visible between the upper lid margin and the iris when looking straight ahead. The lid often has a characteristic temporal flare, sitting highest toward the outer corner rather than in the center.
• Lid lag. When the eye looks down, the upper lid lags behind rather than following smoothly. Aging lids do not do this.
• Lower lid retraction and scleral show. White visible below the iris, because the eye is pushed forward and the lower lid is pulled down by the same process.
• Asymmetry. One eye looks more prominent than the other. Thyroid eye disease is often asymmetric, and a difference of about 2 millimeters or more in forward position between the two sides is a common flag for evaluation.
• Redness and swelling. Redness of the lids, redness over the sides of the white of the eye where the muscles attach, swelling of the conjunctiva (chemosis), and swelling of the small pink fleshy tissue at the inner corner.
• Symptoms. Grittiness, tearing, light sensitivity, aching behind the eye, pain on looking up or sideways, and double vision, especially on waking or looking to one side.

A careful eyelid consultation measures these rather than eyeballing them. The surgeon measures the distance from the lid margin to the center of the pupil on each side, checks how fully the lids close, checks for lid lag, and measures eye prominence with an exophthalmometer, a ruler that reads how far the front of the eye sits from the outer rim of the bony orbit. Normal values differ by ancestry, so asymmetry and change over time matter more than a single number. When the picture suggests thyroid eye disease, CT or MRI of the orbits shows the enlarged muscles and expanded fat, and blood tests including thyroid function and thyroid receptor antibodies support the diagnosis.

Other conditions can produce some of these findings and need to be considered: true ptosis on the opposite side making the normal lid look high, a previous blepharoplasty that removed too much skin, a high myopic (nearsighted) eye that is simply larger, orbital tumors, and inflammation from other causes. Patients with a history of eyelid lumps or recurrent swelling are discussed in the piece on chalazion and stye eyelid lumps, but a lid that is retracted rather than lumpy points in a different direction entirely.

Active versus inactive disease: why timing decides everything

The short answer: thyroid eye disease has an active inflammatory phase that typically lasts from several months to two years or longer, followed by a stable inactive phase; medical treatment works mainly in the active phase, and cosmetic or rehabilitative eyelid surgery should wait until the disease has been inactive and stable, usually for at least six months.

The natural course of thyroid eye disease follows a pattern described decades ago by the British physician Francis Rundle, now known as Rundle's curve. Symptoms build during an active phase, peak, and then improve partway before settling into a plateau. The inactive phase is not a return to normal. Fat expansion, scarred eye muscles, and lid retraction often persist, and that residual change is what surgery addresses.

Clinicians grade activity with tools such as the Clinical Activity Score, a seven-item checklist that gives one point each for:

• Spontaneous aching behind the eye
• Pain with eye movement
• Redness of the eyelids
• Redness of the conjunctiva
• Swelling of the eyelids
• Swelling of the conjunctiva (chemosis)
• Swelling of the caruncle, the small pink tissue at the inner corner

A score of 3 or more out of 7 is generally treated as active disease in the EUGOGO framework. Severity, which is a separate question, depends on how much the lids are retracted, how far forward the eyes are, whether there is double vision, and whether the cornea or optic nerve is threatened.

Why does this matter for eyelid surgery? Three reasons:

• Surgery on active disease is surgery on a moving target. The tissues are swelling and changing. A lid set at a comfortable height in an active phase can be pulled higher or lower as the disease evolves, and the result may need to be redone.
• Inflamed tissue heals less predictably. Bleeding, swelling, and scarring are harder to control in actively inflamed orbital and lid tissue.
• The order of later operations depends on stability. As covered below, eyelid surgery comes last in the sequence. Doing it first, on a patient who later needs orbital decompression or eye muscle surgery, means the lid work may have to be undone.

The exception is urgency. A cornea that is breaking down because the lids cannot close, or an optic nerve under pressure, is treated during the active phase regardless, because vision takes priority over the cosmetic result.

The patient at the top of this piece had radioactive iodine two years earlier and was a former smoker. That history alone is a reason to grade activity before any surgical plan. A patient who has been stable for many months, with no redness, no pain, and unchanged measurements on repeated visits, is in a very different position from one whose eyes are still changing.

Thyroid hormone status also matters for any operation, eyelid or otherwise. Elective surgery under sedation or general anesthesia should wait until thyroid function is controlled, because an uncontrolled overactive thyroid raises the risk of heart rhythm problems and, rarely, a dangerous surge called thyroid storm. The broader approach is covered in the pieces on preoperative testing before cosmetic surgery and cosmetic surgery with autoimmune disease.

Medical treatment: selenium, steroids, teprotumumab, and when it is an emergency

The short answer: mild disease is managed with lubrication, smoking cessation, thyroid control, and often selenium supplements in selenium-deficient regions; moderate to severe active disease is treated with intravenous steroids or teprotumumab, a targeted infusion approved by the FDA in 2020; and loss of color vision or sharpness is an emergency that needs same-day care.

Treatment is matched to activity and severity, and it is the territory of an endocrinologist working with an oculoplastic surgeon or neuro-ophthalmologist, not a cosmetic surgeon alone.

Mild disease. For many patients, the disease is mild and runs its course. Management focuses on comfort and protection: lubricating drops without preservatives, gels or ointments at night, sunglasses, sleeping with the head raised, and taping the lids at night if they do not close fully. Thyroid levels are kept stable, since swings in either direction can aggravate the eyes. Smoking cessation is advised for every patient. In mild active disease, a six-month course of selenium was shown in a randomized trial published in the New England Journal of Medicine in 2011 to improve quality of life and slow progression, and European guidance recommends it, particularly where dietary selenium is low. Whether it adds much in selenium-replete populations such as most of the United States is less clear.

Moderate to severe active disease. Intravenous methylprednisolone given weekly over about 12 weeks has long been the first-line treatment in European guidance, and it reduces inflammation and soft tissue swelling. It does less for established proptosis or scarred muscles, and cumulative doses are capped because of liver and cardiovascular risks. Other options used by specialists include mycophenolate alongside steroids, orbital radiation in selected patients, and biologic drugs used off-label.

Teprotumumab. In January 2020, the FDA approved teprotumumab (sold as Tepezza), an antibody that blocks the insulin-like growth factor 1 receptor, as the first drug specifically for thyroid eye disease. It is given as eight infusions three weeks apart. In its clinical trials it reduced proptosis by a clinically meaningful amount in a majority of patients, which steroids rarely do, and it often improved double vision. It has real limits:

• Hearing. The label carries a warning about hearing impairment, including hearing loss that can be permanent. Baseline and follow-up hearing assessment is part of responsible use.
• Blood sugar. It can raise blood glucose, which matters for patients with diabetes or prediabetes.
• Other effects. Muscle cramps, fatigue, hair thinning, and flares of inflammatory bowel disease have been reported.
• Relapse and cost. Some patients see the eyes move forward again after treatment ends, and the drug is very expensive, so insurance approval often involves documentation of disease severity.

For patients whose main complaint is prominence, the arrival of teprotumumab has changed the conversation. Some who would previously have gone straight to orbital decompression now try the drug first, and some find the cosmetic change is enough to avoid or reduce surgery.

When it is an emergency. Two situations cannot wait. The first is compressive optic neuropathy, in which enlarged muscles crowd the optic nerve at the back of the orbit. Warning signs are colors looking washed out (red appearing faded is a classic description), dimmer or blurrier vision in one eye, or a new blind spot. This needs urgent assessment and is treated with high-dose intravenous steroids, urgent orbital decompression, or both. The second is corneal exposure: severe pain, a red eye, and worsening vision in an eye that cannot close, which risks an ulcer. Either complaint goes to an emergency eye service the same day, not to a cosmetic practice's next opening.

The surgical sequence: decompression, eye muscles, lid retraction, then blepharoplasty

The short answer: when the disease is inactive and stable, surgery follows a fixed order, with orbital decompression first to bring the eyes back, then eye muscle surgery for double vision, then repair of lid retraction, and cosmetic blepharoplasty and fat sculpting last, because each step changes what the next one needs to do.

The traditional sequence for rehabilitative surgery is:

1. Orbital decompression. Bone is removed from one or more walls of the orbit (most often the inner wall and floor, sometimes the outer wall), and orbital fat may also be removed, giving the swollen contents room so the eye can settle back. It is done through incisions hidden inside the eyelid, inside the nose with an endoscope, or at the outer corner. Decompression can create or worsen double vision, which is one reason it comes first.
2. Strabismus surgery. If double vision persists, eye muscle surgery realigns the eyes. Changing the muscles can change lid position, especially the lower lid, so it comes before lid surgery.
3. Eyelid retraction repair. The upper lid is lowered by weakening or recessing the Müller muscle and levator, through the skin or from the underside of the lid, sometimes as a graded full-thickness release. The lower lid is raised by releasing the retractors and sometimes placing a spacer graft (hard palate tissue, ear cartilage, or processed donor dermis are common choices), often combined with outer corner support similar to the techniques in the piece on canthoplasty and fox eye surgery.
4. Blepharoplasty and fat sculpting. Removing skin and the expanded fat of the upper lid and brow, and conservative work on lower lid bags, comes last. In thyroid eye disease the upper lid fullness is often more fat than skin, and the brow fat pad is frequently enlarged, so the operation is closer to debulking than to the skin excision of ordinary aging.

Not every patient needs every step. Many need only lid retraction repair and conservative blepharoplasty. But the order matters even when steps are skipped, because a lid lowered before decompression may end up too low once the eye moves back, and a lower lid tightened before muscle surgery may be pulled down again.

Why a routine blepharoplasty goes wrong. The risks that apply to any eyelid surgery, set out in the piece on revision blepharoplasty for lower lid retraction and hollow eyes, are magnified in an unrecognized thyroid eye:

• Removing upper lid skin from a retracted lid makes it harder to close, and the eye was already exposed. The result can be chronic dryness and corneal damage, the problem described in the earlier piece on dry eye after eyelid surgery.
• Lower blepharoplasty on a prominent eye is high risk for lower lid retraction. When the front of the eye sits ahead of the cheekbone, sometimes called a negative vector, the lower lid has little to rest on, and any skin removal or scar contraction pulls it down further.
• Removing too little fat, or the wrong fat, leaves the fullness in place, because in thyroid eye disease the excess often sits deeper and in the brow, not in the lid fat pads a routine operation targets.
• Surgery during active disease can need to be redone as the tissues keep changing.

Nonsurgical stopgaps. Oculoplastic surgeons sometimes use small doses of botulinum toxin injected into the upper lid to lower a retracted lid temporarily during the active phase, and steroid injections into the lid have been used for active retraction. Hyaluronic acid filler has been used off-label to support a retracted lower lid or to blend a hollow after decompression. These are specialist uses with specific risks; filler near the eye carries the vascular complications covered in the piece on filler vascular occlusion risk, and toxin placed for a cosmetic brow lift, as described in the piece on the Botox brow lift, is a different technique from toxin used to drop a retracted lid.

Who should do it. The surgeon for a thyroid eye is ideally an oculoplastic surgeon, an ophthalmologist with fellowship training in eyelid, orbit, and tear duct surgery (the American Society of Ophthalmic Plastic and Reconstructive Surgery lists members), or a facial plastic surgeon who works in a team with one and with the patient's endocrinologist. A practice that offers a standard blepharoplasty package price without asking about thyroid history, measuring lid position, or checking how fully the eyes close is not assessing the right problem.

Recovery and expectations. Recovery from lid retraction repair resembles ordinary eyelid surgery with more swelling, a point that fits the general pattern in the piece on the swelling timeline after plastic surgery. Upper lid recession results can drift over the first months, and a small revision rate is part of honest counseling. Decompression recovery is longer and carries risks including new or worse double vision, numbness of the cheek and upper lip, sinus problems, and, rarely, vision loss. The goal of the full sequence is eyes that close comfortably, lids at a natural height, and a softer, less startled expression. Restoring the exact pre-disease face is not always possible, and patients should see before-and-after photographs of thyroid patients specifically rather than of routine blepharoplasty.

The honest summary

Thyroid eye disease is an autoimmune condition that swells the fat and muscles around the eye, pushes the eye forward, and pulls the lids open. It is common in Graves disease, can occur with normal thyroid tests or before a thyroid diagnosis, can be triggered or worsened by radioactive iodine, and is made more likely and more severe by smoking. Because it first looks like heavy lids, bags, and a tired stare, it often turns up in cosmetic eyelid consultations.

The key distinction is that aging lids droop while thyroid lids retract. White showing above or below the iris, lid lag on looking down, unequal eye prominence, redness, grittiness, light sensitivity, and double vision all point toward thyroid eye disease. A careful consultation measures lid position, lid closure, and eye prominence, asks about thyroid history, and orders imaging and antibody tests when the picture fits.

Timing decides the plan. Active disease is treated medically, with selenium in some mild cases, intravenous steroids, or teprotumumab, which can shrink proptosis but carries hearing and blood sugar risks. Changes in color vision or sharpness, or a painful eye that cannot close, are emergencies. Surgery waits for stable inactive disease and then follows a fixed order: decompression, eye muscle surgery, lid retraction repair, and cosmetic blepharoplasty last.

The patient at the top of this piece was examined by a surgeon who asked about the thyroid, measured a millimeter and a half of white above each iris, found mild lid lag and incomplete closure on the right, and graded the disease as inactive after reviewing photographs from the past year. There was no double vision and only mild prominence. The plan was not a blepharoplasty package. It was an upper lid recession on both sides with conservative removal of the expanded fat, no lower lid skin removal, and a referral back to the endocrinologist to keep thyroid levels steady. The stare softened, the eyes closed fully, and the grittiness mostly resolved. The colleagues stopped asking whether anything was wrong, which was the point of the appointment in the first place.